NASDAQ:LEGN

Legend Biotech (LEGN) Stock Forecast, Price & News

$67.17

-0.14 (-0.21%)

(As of 09/29/2023 ET)

Compare

Today's Range: $66.72
▼
$68.23
50-Day Range: $63.16
▼
$76.50
52-Week Range: $37.30
▼
$77.32

Volume: 525,950 shs
Average Volume: 442,805 shs
Market Capitalization: $11.09 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $80.90

Legend Biotech MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.87 Rating Score
Upside/Downside: 20.4% Upside
$80.90 Price Target
Short Interest: Bearish
4.37% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.60) to ($1.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

893rd out of 972 stocks

Pharmaceutical Preparations Industry

412th out of 444 stocks

2.4

Analyst's Opinion

Consensus Rating
Legend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $80.90, Legend Biotech has a forecasted upside of 20.4% from its current price of $67.17.
Amount of Analyst Coverage
Legend Biotech has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.37% of the outstanding shares of Legend Biotech have been sold short.
Short Interest Ratio / Days to Cover
Legend Biotech has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Legend Biotech has recently decreased by 2.83%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Legend Biotech does not currently pay a dividend.
Dividend Growth
Legend Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LEGN.

2.7

News and Social Media Coverage

News Sentiment
Legend Biotech has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Legend Biotech this week, compared to 3 articles on an average week.
Search Interest
4 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Legend Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.02% of the stock of Legend Biotech is held by insiders.
Percentage Held by Institutions
49.61% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Legend Biotech are expected to grow in the coming year, from ($2.60) to ($1.61) per share.
Price to Book Value per Share Ratio
Legend Biotech has a P/B Ratio of 14.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Legend Biotech (NASDAQ:LEGN) Stock

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Price History

30 days | 90 days | 365 days | Advanced Chart

LEGN Stock News Headlines

September 25, 2023 | americanbankingnews.com

Legend Biotech Co. (NASDAQ:LEGN) Receives $80.90 Average Target Price from Analysts

August 21, 2023 | seekingalpha.com

Legend Biotech: Working On Supply Issues

October 1, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 16, 2023 | markets.businessinsider.com

Legend Biotech (LEGN) Receives a Buy from Barclays

August 16, 2023 | finance.yahoo.com

Q2 2023 Legend Biotech Corp Earnings Call

August 15, 2023 | finance.yahoo.com

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

August 14, 2023 | finance.yahoo.com

Why Earnings Season Could Be Great for Legend Biotech (LEGN)

August 3, 2023 | finance.yahoo.com

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

October 1, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

July 21, 2023 | msn.com

Morgan Stanley Maintains Legend Biotech Corp - ADR (LEGN) Overweight Recommendation

July 7, 2023 | seekingalpha.com

Despite High Share Price, Legend Bio Looks Like A Winner

June 29, 2023 | finance.yahoo.com

This Top-Performing Small-Cap Manager Is Betting Big on China

June 12, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Legend Biotech (LEGN)

June 7, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Legend Biotech (LEGN)

June 7, 2023 | finance.yahoo.com

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

June 7, 2023 | msn.com

HC Wainwright & Co. Maintains Legend Biotech Corp - ADR (LEGN) Buy Recommendation

June 6, 2023 | finance.yahoo.com

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

June 5, 2023 | finance.yahoo.com

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

May 25, 2023 | markets.businessinsider.com

Expert Ratings for Legend Biotech

May 25, 2023 | msn.com

William Blair Initiates Coverage of Legend Biotech Corp - ADR (LEGN) with Market Perform Recommendation

May 25, 2023 | finance.yahoo.com

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

May 23, 2023 | finance.yahoo.com

Legend Biotech's Story Is Still Playing Out

May 22, 2023 | msn.com

HC Wainwright & Co. Reiterates Legend Biotech Corp - ADR (LEGN) Buy Recommendation

May 22, 2023 | msn.com

Daiwa Capital Initiates Coverage of Legend Biotech Corp - ADR (LEGN) with Buy Recommendation

May 19, 2023 | msn.com

Barclays Maintains Legend Biotech Corp - ADR (LEGN) Overweight Recommendation

May 19, 2023 | msn.com

RBC Capital Maintains Legend Biotech Corp - ADR (LEGN) Outperform Recommendation

May 19, 2023 | markets.businessinsider.com

Piper Sandler Sticks to Their Buy Rating for Legend Biotech (LEGN)

See More Headlines

Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

LEGN Company Calendar

Last Earnings: 8/15/2023
Today: 9/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LEGN
CUSIP: N/A
CIK: 1801198
Web: www.legendbiotech.com
Phone: 732-317-5050
Fax: N/A
Employees: 1,390
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $80.90
High Stock Price Forecast: $92.00
Low Stock Price Forecast: $64.00
Forecasted Upside/Downside: +20.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.87
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 8.01
Quick Ratio: 7.93

Sales & Book Value

Annual Sales: $164.66 million
Price / Sales: 67.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.54 per share
Price / Book: 14.80

Miscellaneous

Outstanding Shares: 165,067,000
Free Float: 165,034,000
Market Cap: $11.09 billion
Optionable: Not Optionable
Beta: 0.02

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Ying Huang Ph.D. (Age 50)
CEO & Director

Ms. Lori A. Macomber CPA (Age 52)
Chief Financial Officer

Dr. Guowei Fang Ph.D.
Chief Scientific Officer & Head of Bus. Devel.

Joanne Choi
Sr. Mang. of Investor Relations

Deborah Wong
Exec. Director of Strategic Marketing & Corp. Communications

Ms. Elaine Qian
VP & Global Head of HR

Ms. Liz Gosen
Sr. VP of Technical Operations

Dr. Yuhong Qiu Ph.D.
Sr. VP of Global Regulatory Affairs

Mr. Steven J. Gavel
Sr. VP of Commercial Devel., US & Europe

Mr. Alan Kick
Sr. VP of Global Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LEGN Stock - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings or view top-rated stocks.
What is Legend Biotech's stock price forecast for 2023?: 15 brokers have issued 1 year target prices for Legend Biotech's shares. Their LEGN share price forecasts range from $64.00 to $92.00. On average, they anticipate the company's share price to reach $80.90 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts.
How have LEGN shares performed in 2023?: Legend Biotech's stock was trading at $49.92 at the beginning of 2023. Since then, LEGN shares have increased by 34.6% and is now trading at $67.17.
View the best growth stocks for 2023 here.
How were Legend Biotech's earnings last quarter?: Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Tuesday, August, 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.21. The business earned $73.30 million during the quarter, compared to analysts' expectations of $56.64 million. The business's quarterly revenue was up 510.8% compared to the same quarter last year.
What ETFs hold Legend Biotech's stock?: ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Global X MSCI China Health Care ETF (CHIH), Loncar China Biopharma ETF (CHNA), Harbor Health Care ETF (MEDI), Virtus LifeSci Biotech Products ETF (BBP), KraneShares MSCI All China Health Care Index ETF (KURE), Fidelity Disruptive Medicine ETF (FMED), BlackRock Future Health ETF (BMED) and Range Cancer Therapeutics ETF (CNCR).
What other stocks do shareholders of Legend Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?: (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.
What is Legend Biotech's stock symbol?: Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN."
How do I buy shares of Legend Biotech?: Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Legend Biotech's stock price today?: One share of LEGN stock can currently be purchased for approximately $67.17.
How much money does Legend Biotech make?: Legend Biotech (NASDAQ:LEGN) has a market capitalization of $11.09 billion and generates $164.66 million in revenue each year.
How many employees does Legend Biotech have?: The company employs 1,390 workers across the globe.
How can I contact Legend Biotech?: Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The official website for the company is www.legendbiotech.com. The company can be reached via phone at 732-317-5050 or via email at investor@legendbiotech.com.

This page (NASDAQ:LEGN) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial